Why is "Anti-PD-1" trending?

Search Interest Perspective

• Adjuvant Anti-PD-1 Boosts OS in Matched Melanoma Cases - medscape.com
• Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial - Nature
• Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC - henlius.com
• A New Model of PD-1 Inhibition: Unphosphorylated Tyrosines Block T-Cell Signaling Condensate Formation - Oncodaily
• Independent research teams validate Apeximmune's PLA2G2D target for overcoming anti-PD-1 resistance - allsci.com
• Anti-PD-1 monoclonal antibody combined with chemotherapy for porocarcinoma: a case report and literature review - Frontiers
• CD24 Expression Confers Resistance to Anti–PD-1 Therapy in NSCLC, RET-TKI Dose Reductions Do Not Compromise Outcomes in RET+ Disease - OncLive
• PD-1 signaling and PD-1 blockade–mediated tumor control are established at microvillar T cell contacts - Science | AAAS
• Vitamin A Derivative Could Help Immune Cells Fight Brain Cancer - Technology Networks
• FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma - CancerNetwork
• Anti-PD-1 plus anti-CTLA-4 blockade overcomes immune exclusion in NSCLC brain metastases by enhancing CD8 - Nature
• Enhancing Non-small Cell Lung Cancer Susceptibility to Anti-PD-1/PD-L1 Therapy through PD-L1 Ligand–Ir(III) Complex Conjugates - Science Partner Journals
• Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma - Nature
• PLA2G2D in tumour-draining lymph nodes regulates anti-tumour immunity - Nature
• Anti-PD-1 plus nab-paclitaxel and bevacizumab for second-line treatment of cancer of unknown primary (Fudan CUP-002): a phase II trial - Nature
• Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1 - Nature
• Erythrocyte–anti-PD1 conjugates in persons with advanced solid tumors resistant to anti-PD1/PDL1: preclinical characterization and results of a phase 1 trial - Nature
• Predicting anti-PD-1 immune checkpoint blockade response in melanoma patients with spatially aware machine learning models - Nature
• A clinic-responder-derived defined microbial consortium enhances anti-PD-1 immunotherapy efficacy in mice - Nature
• TRIM21-mediated degradation of HILPDA overcomes anti-PD-1 immunotherapy resistance in breast cancer by limiting PD-L1 palmitoylation - Nature
• Anti-PD-1 immune checkpoint inhibitor-induced cardiotoxicity is associated with dysfunctional metabolism, muscle wasting and autophagy - Nature
• Case Report: Anti-PD-1 therapy as a catalyst for the rapid transformation of a hepatic nodule into HCC: a “soil and seed” paradox in metachronous triple primary malignancies? - Frontiers
• RP1/Nivolumab Shows OS Benefit in Anti-PD-1-Progressed Melanoma - CancerNetwork
• Cellular reprogramming during anti-PD-1 and chemotherapy treatment in early-stage primary hormone receptor-positive breast cancer - Nature
• Cordyceps sinensis enhances the efficacy of anti-PD-1 immunotherapy in Lewis lung adenocarcinoma - Nature
• Radiotherapy Regimen Shows Responses in Anti–PD-1–Refractory NSCLC - CancerNetwork
• Molecular remodeling of cancer-associated fibroblasts in breast cancer patients receiving anti–PD-1 immunotherapy - Frontiers
• FDA Advisory Committee to Weigh RP1 Plus Nivolumab in Anti–PD-1–Pretreated Advanced Melanoma - OncLive
• Radiotherapy combined with anti-PD-1 immunotherapy promotes ferroptosis-driven control of hepatocellular carcinoma - Nature
• Novel anti-LAG-3 antibody LBL-007 with anti-PD-1 blockade enhances antitumor immunity by promoting T cell-induced apoptosis - Nature
• Genistein enhances anti-PD-1 efficacy in melanoma by suppressing regulatory T cell differentiation and activity - Nature
• The relationship between galectin-1 expression and the efficacy of anti-PD-1 therapy for non-small cell lung cancer patients - Nature
• Phase 3 LITESPARK-011 Trial Positions Belzutifan Plus Lenvatinib as Potential Option Post Anti–PD-L1/Anti–PD-1 Therapy in aRCC - ASCO Daily News
• Case Report: Neurological immune-related adverse events with anti-PD-1 based immunotherapy in cervical cancer - Frontiers
• Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: a randomized, placebo-controlled phase 1b study - Nature
• JAK inhibition in PD-1 immunotherapy and tumor microenvironment - Frontiers
• Novel immunotherapy demonstrates early potential to overcome resistance to immune checkpoint therapy - UT MD Anderson
• EMITT-1 Study: GRWD5769 Plus Cemiplimab in Anti–PD-1–Resistant Solid Tumors and MSS Colorectal Cancer - Oncodaily
• Surufatinib plus anti-PD-1/PD-L1 antibody as second-line therapy for advanced biliary tract cancer: A single-centre investigator-initiated trial - Wiley Online Library
• Anti-PD-1 Nanobody-Armored MSLN CAR-T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies - Wiley & Sons
• Predicting Benefit From TIL Therapy After Progression: Clinical, Tumor, and TIL Characteristics May Hold Clues - ASCO Daily News
• Cellular neighborhoods inside tumors may predict which patients with melanoma benefit from combination immunotherapy - UCLA Health
• PD-1/PD-L1 blockade in HIV-associated advanced lung cancer: from mechanisms to clinical practice - Frontiers
• Rapid progression to toxic epidermal necrolysis following switch of PD-1 inhibitors: a case report - Frontiers
• Modulating AP-1 enables CAR T cells to establish an intratumoral stemlike reservoir and overcomes resistance to PD-1 blockade - Science | AAAS
• Summit’s PD-1/VEGF to take center stage at ASCO, with wide impact for peers - BioSpace
• Advances in PD-1 and CTLA-4 dual-target immunotherapy for ovarian cancer - Frontiers
• Opinion: The real potential of PD-(L)1×VEGF bispecifics may be outside lung cancer - BioSpace
• Evaluation of warning strategies for paraneoplastic neurological syndromes associated with PD-1/PD-L1 inhibitors - Frontiers
• International Analysis of Anti-PD-1/PD-L1 Efficacy and Biomarker Selection in Mismatch Repair-Deficient mCRPC - Niven Mehra - UroToday
• Summit shares descend as PD-1/VEGF asset misses early survival mark - BioSpace
• Merck’s early PD-1/VEGF data competitive in lung cancer, but Summit ‘looms large’ - BioSpace
• Oncolytic Immunotherapy Yields Responses in Refractory Melanoma - emjreviews.com
• PD-1/PDL-1 Inhibitor Market - Future Market Insights
• Eisai signs $388m deal for Japanese rights to Henlius’ anti-PD-1 mAb - Pharmaceutical Technology
• JNJ-190 Plus Anti–PD-1 Immune Checkpoint Inhibitors Generate Early Antitumor Activity in HNSCC - OncLive
• P-RAD Trial Shows Increased T-Cell Infiltration With Preoperative Radiation Added to Anti-PD-1 Therapy in Early Breast Cancer - The ASCO Post
• EAU 2026: Phase 1/2 Study of an Anti-PD-L1/IL-15 Variant Fusion Protein (SIM0237) in BCG Unresponsive High-Risk NMIBC - UroToday
• PD-1/PD-L1 Checkpoint Dysfunction in Vitiligo: Novel Pathogenic Insights and Therapeutic Innovation - Wiley Online Library
• Immune Profiling Predicts Response to Radiation and Anti-PD-1 in Kidney Cancer - Bioengineer.org
• PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis - GlobeNewswire
• Neoadjuvant Anti–PD-1 Therapy With Prolgolimab in Locally Advanced dMMR/MSI Colorectal Cancer - Oncodaily
• AACR: Merck unveils PD-1xVEGF bispecific data in NSCLC, remains tight-lipped on phase 3 plans - Fierce Biotech
• Early Immunotherapy Shows Promising Results in Advanced Basal Cell Carcinoma - Johns Hopkins Medicine
• Exploring synergy to keep the immunotherapy flame alight - ESMO Daily Reporter
• How tumors evade immunotherapy: DDB1 sends PD-L1 into nuclei, driving anti-PD-1 resistance - Bioengineer.org
• Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy - Nature
• Meiji Seika Pharma Initiates Phase I Clinical Trial in Australia Evaluating ME3241, an Anti-PD-1 Agonist Antibody Discovered Through Collaborative Research With FBRI - Business Wire
• Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours - Nature
• Razelle Kurzrock: High PD-L2 RNA Correlates With Longer Survival After Anti-PD-1 Immunotherapy - Oncodaily
• Overcoming resistance to immune checkpoint inhibitor in non-small cell lung cancer: the promise of combination therapy - Frontiers
• PD-1 Blockade Enhances Therapeutic Effects of Anti-CEA - Wiley Online Library
• Anti-PD-1 treatment response is associated with the influx of circulating myeloid and T-cell subsets into the metastatic melanoma tumor microenvironment | British Journal of Cancer - Nature
• Tanja Obradovic: Anti-PD-1 x VEGF Bispecifics Race in the Late-Stage Clinical Development Gets Intense - Oncodaily
• Comprehensive immunophenotyping reveals distinct tumor microenvironment alterations in anti-PD-1 sensitive and resistant syngeneic mouse model - Nature
• Anti-PD-1 cis-delivery of low-affinity IL-12 activates intratumoral CD8+T cells for systemic antitumor responses - Nature
• Anti-PD-1 therapy triggers Tfh cell–dependent IL-4 release to boost CD8 T cell responses in tumor-draining lymph nodes | Journal of Experimental Medicine - Rockefeller University Press
• Biomarkers of response to PD-1 pathway blockade - British Journal of Cancer - Nature
• Resistance to anti-LAG-3 plus anti-PD-1 therapy in head and neck cancer is mediated by Sox9+ tumor cells interaction with Fpr1+ neutrophils - Nature
• Anti–PD-1 cancer immunotherapy induces central nervous system immune-related adverse events by microglia activation - Science | AAAS
• Combination of PD-1/PD-L1 and CTLA-4 inhibitors in the treatment of cancer – a brief update - Frontiers
• Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations - Frontiers
• Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody - Nature
• Mature and migratory dendritic cells promote immune infiltration and response to anti-PD-1 checkpoint blockade in metastatic melanoma - Nature
• Active recruitment of anti–PD-1–conjugated platelets through tumor-selective thrombosis for enhanced anticancer immunotherapy - Science | AAAS
• Resistance to anti-PD-1 therapy is driven by CD30 - Nature
• Systematic investigation of chemo-immunotherapy synergism to shift anti-PD-1 resistance in cancer - Nature
• Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype - Nature
• Novel immune drug combination induces tumour microenvironment remodelling and reduces the dosage of anti-PD-1 antibody - Nature
• Different tumour-resident memory T-cell subsets regulate responses to anti-PD-1 and anti-CTLA-4 cancer immunotherapies - Nature
• Inhibition of MBTPS1 enhances antitumor immunity and potentiates anti-PD-1 immunotherapy - Nature
• Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers - Nature
• Bifidobacterium boosts anti-PD-1 effectiveness through JAK pathway in hepatocellular carcinoma - Nature
• Anti-PD-1 exacerbates bleomycin-induced lung injury in mice via Caspase-3/GSDME-mediated pyroptosis - Nature
• Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial - Nature
• Addition of metformin to anti-PD-1/PD-L1 drugs activates anti-tumor immune response in peripheral immune cells of NSCLC patients - Nature
• PD-1 receptor deficiency enhances CD30+ Treg cell function in melanoma | Nature Immunology - Nature
• The response to anti–PD-1 and anti–LAG-3 checkpoint blockade is associated with regulatory T cell reprogramming - Science | AAAS
• Dual TIGIT and PD-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-PD-1 therapies: the phase 2 LIVERTI trial - Nature
• Exploratory phase II trial of an anti-PD-1 antibody camrelizumab combined with a VEGFR-2 inhibitor apatinib and chemotherapy as a neoadjuvant therapy for triple-negative breast cancer (NeoPanDa03): efficacy, safety and biomarker analysis - Nature